GlassScriptPhysician profile
Oscar R Guerra
NPI 1801818232
$10,246.24
in general payments reported to CMS, 2019-2025
11 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.01 · 2022: $6,819 · 2023: $2,828 · 2024: $286 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,501 · Food and Beverage: $895 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,501.30 |
| Food and Beverage | $894.67 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $5,002.60 | 2022-2023 | |
| Ge Healthcare | $4,280.00 | 2022 | |
| Heartflow, INC. | $353.02 | 2023-2025 | Ffrct |
| Boston Scientific Corporation | $288.25 | 2023-2024 | Emerge Push, Avvigo Guidance System |
| Alnylam Pharmaceuticals INC. | $140.62 | 2025 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $72.57 | 2023-2024 | Edarbi, Edarbi |
| Surmodics, INC. | $38.21 | 2022-2025 | Pounce LP Thrombectomy, Pounce Thrombectomy System, Pounce Thrombectomy |
| Abbott Laboratories | $25.22 | 2024 | Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Guerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.